45013 D1 Dymo Compatible Label 3 Tape 300 420P 280 160 LabelManager 7m x 12mm Label Makers


  1. Home
  2. 45013 D1 Dymo Compatible Label 3 Tape 300 420P 280 160 LabelManager 7m x 12mm
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
3 Label Compatible Dymo D1 45013 Tape 12mm x 7m LabelManager 160 280 420P 300
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

Unbranded/Generic

Compatible Model2: LabelManager 220P 260P 280 300 350 350D 360D MPN:

RRDA45013 3 04

Compatible Model3: LabelManager 400 420P 450 450D 500TS Type: Labels
Compatible Model4: LabelManager PC PC II PnP PnP Wireless Model:

45013

Compatible Model5: LabelPoint 100 150 200 250 300 350 Color:

Black on White

Compatible Model6: LabelWriter Duo Duo 400 Duo 450 Compatible Brand: For Dymo
Compatible Model7: LabelMaker PC PC2 Compatible Model: LabelManager 100 120P 150 155 160 200 210D
Compatible Model8: RHINO 4200 5000 5200 6000 Manufacturer Warranty: 2 years
Compatible Model9: 2000 3500 4500 5000 5500 Product: IB-RRDA45013
Dimensions: 12mm x 7m Pack Size: 3
UPC:

Does not apply

published on tue nov 09 2021

45013 D1 Dymo Compatible Label 3 Tape 300 420P 280 160 LabelManager 7m x 12mm Label Makers

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

45013 D1 Dymo Compatible Label 3 Tape 300 420P 280 160 LabelManager 7m x 12mm Label Makers

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS